Table 5.

The adjusted risk of the composite cardiovascular endpoint of myocardial infarction, stroke, or cardiovascular death according to the presence of a detectable hsTnT in women with and without diabetes in the Women’s Health Study.

	Diabetic Women*		Non-Diabetic Women†
	Hazard Ratio (95% CI)	P-value	Hazard Ratio (95% CI)	P-value
Model 1	1.95 (1.17-3.23)	0.010	1.07 (0.81-1.40)	0.63
Model 2	1.85 (1.09-3.17)	0.024	1.13 (0.82-1.54)	0.45
Model 3	1.79 (1.04-3.07)	0.036	1.13 (0.82-1.55)	0.46
Model 4	1.76 (1.00-3.08)	0.0499	1.15 (0.82-1.59)	0.42

^*65 out of 512 diabetic women developed the composite cardiovascular endpoint during follow up.

^†The case-cohort study of non-diabetic women included 479 cases of the composite cardiovascular endpoint and a reference subcohort of 564 women.

Model 1: Age, race adjusted

Model 2: Age, race, body mass index (kg/m2), history of hypertension, current smoking, parental history of myocardial infarction, total cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL), natural logarithm high-sensitivity C-reactive protein (mg/L).

Model 3: Model 2 plus hemoglobin A1c (%)

Model 4: Model 2 plus hemoglobin A1c (%) and the natural logarithms of NT-proBNP and estimated glomerular filtration rate.